Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...
The estimated glomerular filtration rate (eGFR) is a blood test to assess kidney function. The formula for calculating eGFR takes the patient’s body size, age, and sex into account to predict how well ...
EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...
A retrospective analysis of 1,804 patients with NSCLC undergoing next-generation sequencing (NGS) in 2019-2024 at University Hospital Würzburg (single-center cohort, including 15 patients with ...
Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...
Black Diamond Therapeutics, Inc. (BDTX) is a clinical-stage oncology company developing therapies that target families of oncogenic mutations in patients with cancer. Cullinan Therapeutics, Inc. (CGEM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results